BTB06584/ supplier with competitive price in stock-Rechems

Details:

BTB06584 is an IF1-dependent selective inhibitor of the mitochondrial F1Fo-ATPase.Target: ATPase in vitro: BTB06584 inhibits F1Fo-ATPase activity with no effect on ΔΨm or O2 consumption.ATP consumption was decreased following inhibition of respiration, and ischaemic cell death was reduced.BTB06584 efficiency was increased by IF1 overexpression and reduced by silencing the protein.BTB06584 may represent a valuable tool to selectively inhibit mitochondrial F1Fo-ATPase activity without compromising ATP synthesis and to limit ischaemia-induced injury caused by reversal of the mitochondrial F1Fo-ATPsynthase.in vivo: BTB06584 rescues defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the Atpif1a gene is lost.
Shanghai Rechem science Co., Ltd.
Rechemsis focus on R&D of new APIS, signal transduction inhibitors and pharmaceutical intermediates. We follow closely the industry trend, and the latest research achievements in life science area.
Rechems is located in the largest biomedical base in China--Shanghai and cooperatively established modern production base and laboratory in surrounding areas. We have built up a good relationship with many US / European / Japanese pharmaceutical companies to conduct chemical research and inventory trading in medicinal chemistry.
Rechems's mission is to serve pharmaceutical community by providing excellent services and high-quality products in a timely manner.
Rechems's vision is to be recognized by our clients as one of the best suppliers of chemical products for our superior quality, efficient and cost-effective services.
We insist the principle of "Quality first, customer foremost, best credit, be pioneering and creative", looking forward to establishing good business relationships with customers all over the world. Let's work together for bright future!